Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.

Pulmonary vaccination is a promising route for immunization against tuberculosis because the lung is the natural site of infection with Mycobacterium tuberculosis. Yet, adjuvants with a suitable safety profile need to be found to enhance mucosal immunity to recombinant antigens. The aim of this stud...

Full description

Bibliographic Details
Main Authors: Julie Todoroff, Muriel M Lemaire, Catherine Fillee, Fabienne Jurion, Jean-Christophe Renauld, Kris Huygen, Rita Vanbever
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3651129?pdf=render
_version_ 1818778065281482752
author Julie Todoroff
Muriel M Lemaire
Catherine Fillee
Fabienne Jurion
Jean-Christophe Renauld
Kris Huygen
Rita Vanbever
author_facet Julie Todoroff
Muriel M Lemaire
Catherine Fillee
Fabienne Jurion
Jean-Christophe Renauld
Kris Huygen
Rita Vanbever
author_sort Julie Todoroff
collection DOAJ
description Pulmonary vaccination is a promising route for immunization against tuberculosis because the lung is the natural site of infection with Mycobacterium tuberculosis. Yet, adjuvants with a suitable safety profile need to be found to enhance mucosal immunity to recombinant antigens. The aim of this study was to evaluate the immunogenicity, the safety and the protective efficacy of a subunit vaccine composed of the immunodominant mycolyl-transferase antigen 85A (Ag85A) and one of three powerful mucosal adjuvants: the oligodeoxynucleotide containing unmethylated cytosine-phosphate-guanine motifs (CpG), the monophosphoryl lipid A of Salmonella minnesota (MPLA) or the B subunit of heat-labile enterotoxin of Escherichia coli (LTB). BALB/c mice were vaccinated in the deep lungs. Our results showed that lung administration of these adjuvants could specifically induce different types of T cell immunity. Both CpG and MPLA induced a Th-1 type immune response with significant antigen-specific IFN-γ production by spleen mononuclear cells in vitro and a tendency of increased IFN-γ in the lungs. Moreover, MPLA triggered a Th-17 response reflected by high IL-17A levels in the spleen and lungs. By contrast, LTB promoted a Th-2 biased immune response, with a production of IL-5 but not IFN-γ by spleen mononuclear cells in vitro. CpG did not induce inflammation in the lungs while LTB and MPLA showed a transient inflammation including a neutrophil influx one day after pulmonary administration. Pulmonary vaccination with Ag85A without or with MPLA or LTB tended to decrease bacterial counts in the spleen and lungs following a virulent challenge with M. tuberculosis H37Rv. In conclusion, CpG and MPLA were found to be potential adjuvants for pulmonary vaccination against tuberculosis, providing Th-1 and Th-17 immune responses and a good safety profile.
first_indexed 2024-12-18T11:38:48Z
format Article
id doaj.art-dcaab0b2e022487d97a58d6fb85c8530
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-18T11:38:48Z
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-dcaab0b2e022487d97a58d6fb85c85302022-12-21T21:09:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0185e6334410.1371/journal.pone.0063344Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.Julie TodoroffMuriel M LemaireCatherine FilleeFabienne JurionJean-Christophe RenauldKris HuygenRita VanbeverPulmonary vaccination is a promising route for immunization against tuberculosis because the lung is the natural site of infection with Mycobacterium tuberculosis. Yet, adjuvants with a suitable safety profile need to be found to enhance mucosal immunity to recombinant antigens. The aim of this study was to evaluate the immunogenicity, the safety and the protective efficacy of a subunit vaccine composed of the immunodominant mycolyl-transferase antigen 85A (Ag85A) and one of three powerful mucosal adjuvants: the oligodeoxynucleotide containing unmethylated cytosine-phosphate-guanine motifs (CpG), the monophosphoryl lipid A of Salmonella minnesota (MPLA) or the B subunit of heat-labile enterotoxin of Escherichia coli (LTB). BALB/c mice were vaccinated in the deep lungs. Our results showed that lung administration of these adjuvants could specifically induce different types of T cell immunity. Both CpG and MPLA induced a Th-1 type immune response with significant antigen-specific IFN-γ production by spleen mononuclear cells in vitro and a tendency of increased IFN-γ in the lungs. Moreover, MPLA triggered a Th-17 response reflected by high IL-17A levels in the spleen and lungs. By contrast, LTB promoted a Th-2 biased immune response, with a production of IL-5 but not IFN-γ by spleen mononuclear cells in vitro. CpG did not induce inflammation in the lungs while LTB and MPLA showed a transient inflammation including a neutrophil influx one day after pulmonary administration. Pulmonary vaccination with Ag85A without or with MPLA or LTB tended to decrease bacterial counts in the spleen and lungs following a virulent challenge with M. tuberculosis H37Rv. In conclusion, CpG and MPLA were found to be potential adjuvants for pulmonary vaccination against tuberculosis, providing Th-1 and Th-17 immune responses and a good safety profile.http://europepmc.org/articles/PMC3651129?pdf=render
spellingShingle Julie Todoroff
Muriel M Lemaire
Catherine Fillee
Fabienne Jurion
Jean-Christophe Renauld
Kris Huygen
Rita Vanbever
Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.
PLoS ONE
title Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.
title_full Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.
title_fullStr Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.
title_full_unstemmed Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.
title_short Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.
title_sort mucosal and systemic immune responses to mycobacterium tuberculosis antigen 85a following its co delivery with cpg mpla or ltb to the lungs in mice
url http://europepmc.org/articles/PMC3651129?pdf=render
work_keys_str_mv AT julietodoroff mucosalandsystemicimmuneresponsestomycobacteriumtuberculosisantigen85afollowingitscodeliverywithcpgmplaorltbtothelungsinmice
AT murielmlemaire mucosalandsystemicimmuneresponsestomycobacteriumtuberculosisantigen85afollowingitscodeliverywithcpgmplaorltbtothelungsinmice
AT catherinefillee mucosalandsystemicimmuneresponsestomycobacteriumtuberculosisantigen85afollowingitscodeliverywithcpgmplaorltbtothelungsinmice
AT fabiennejurion mucosalandsystemicimmuneresponsestomycobacteriumtuberculosisantigen85afollowingitscodeliverywithcpgmplaorltbtothelungsinmice
AT jeanchristopherenauld mucosalandsystemicimmuneresponsestomycobacteriumtuberculosisantigen85afollowingitscodeliverywithcpgmplaorltbtothelungsinmice
AT krishuygen mucosalandsystemicimmuneresponsestomycobacteriumtuberculosisantigen85afollowingitscodeliverywithcpgmplaorltbtothelungsinmice
AT ritavanbever mucosalandsystemicimmuneresponsestomycobacteriumtuberculosisantigen85afollowingitscodeliverywithcpgmplaorltbtothelungsinmice